QUOTE AND NEWS
SeekingAlpha  Sep 18  Comment 
By Trevor Lowenthal: Opexa (NASDAQ:OPXA) stock has tanked ever since the company announced plans to conduct a near-term public offering. In a rather unusual move, however, management suddenly terminated the offering, leaving many shareholders...
SeekingAlpha  Sep 16  Comment 
By Trevor Lowenthal: In April, I wrote a PRO article on Opexa Therapeutics (NASDAQ:OPXA) with a thesis stating that ongoing clinical success of Opexa's lead drug candidate, Tcelna (imilecleucel-T), could translate to regulatory approval and...
StreetInsider.com  Sep 15  Comment 
Majesco Entertainment (NASDAQ: COOL) 20.8% LOWER; reported Q3 EPS of ($0.58), $0.16 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $2.9 million versus the consensus estimate of $6.1 million. The Board of Directors...
DailyFinance  Sep 15  Comment 
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS), today announced that it intends to offer shares of its common stock in an underwritten public offering. All of...
SeekingAlpha  Sep 9  Comment 
By Trevor Lowenthal: In April, I wrote a PRO article on Opexa Therapeutics (NASDAQ:OPXA) with a thesis stating that ongoing clinical success of Opexa's lead drug candidate, Tcelna (imilecleucel-T), could translate to regulatory approval and...
SeekingAlpha  Aug 15  Comment 
By Trevor Lowenthal: In April, I wrote a PRO article on Opexa Therapeutics (NASDAQ:OPXA) with a thesis stating that ongoing clinical success of Opexa's lead drug candidate, Tcelna (imilecleucel-T), could translate to regulatory approval and...
SeekingAlpha  Aug 15  Comment 
By SA Transcripts: Opexa Therapeutics Inc (NASDAQ:OPXA) Q2 2014 Earnings Conference Call August 14, 2014 5:00 PM ET Executives Neil Warma - Chief Executive Officer Karthik Radhakrishnan - Chief Financial Officer Analysts ...
SeekingAlpha  Jun 3  Comment 
By Len Zehr: With its Phase IIb clinical trial in secondary-progressive multiple sclerosis (SPMS) running nicely, Opexa Therapeutics (OPXA) is considering adding a new disease indication to its antigen-specific T-cell immunotherapy platform. "We...
StreetInsider.com  May 13  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Opexa+%28OPXA%29+Reaches+Enrollment+Target+in+Ph+IIb+Trial+of+Secondary+Progressive+Multiple+Sclerosi/9476959.html for the full story.
SeekingAlpha  Apr 30  Comment 
By Trevor Lowenthal: Today we are considering a long position in an emerging micro cap called Opexa Therapeutics (OPXA). This company operates within the biopharmaceutical sector, has a $45 million market cap and is listed on the Nasdaq. One of...





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki